Table 5.
Results of the scenario analyses
| Scenario | ΔQALY | ΔCosts | ICER |
|---|---|---|---|
| Base case values | |||
| - 5-grass tablet vs. allergoid mix | 0.036 | € 458 | € 12,593 |
| - 5-grass tablet vs. symptomatic tx | 0.081 | € 1,385 | € 17,007 |
| Scenario analysis 1: 100% Lump sums | |||
| - 5-grass tablet vs. allergoid mix | 0.036 | € 546 | € 15,025 |
| - 5-grass tablet vs. symptomatic tx | 0.081 | € 1,362 | € 16,723 |
| Scenario analysis 2: 100% Public to private (ambulatory) | |||
| - 5-grass tablet vs. allergoid mix | 0.036 | € 305 | € 8,400 |
| - 5-grass tablet vs. symptomatic tx | 0.081 | € 1,414 | € 17,367 |
| Scenario analysis 3: Societal perspective | |||
| - 5-grass tablet vs. allergoid mix | 0.036 | € 339 | € 9,327 |
| - 5-grass tablet vs. symptomatic tx | 0.081 | € 784 | € 9,634 |
| Scenario analysis 4: Changing utilities | |||
| - 5-grass tablet vs. allergoid mix | 0.026 | € 458 | € 17,531 |
| - 5-grass tablet vs. symptomatic tx | 0.131 | € 1,385 | € 10,557 |
| Scenario analysis 5: Shorter pollen season | |||
| - 5-grass tablet vs. allergoid mix | 0.024 | € 266 | € 10,966 |
| - 5-grass tablet vs. symptomatic tx | 0.055 | € 1,198 | € 21,918 |